297 results on '"Aerts, Joachim G.J.V."'
Search Results
2. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
3. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction
4. Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989–2020
5. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands
6. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study
7. Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
8. Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose
9. Figure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
10. Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
11. Supplementary Tables S1-S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy
12. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
13. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition
14. Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer.
15. Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses
16. Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
17. Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
18. Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib.
19. Data from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
20. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
21. Acute COVID-19 treatment is not associated with health problems 2 years after hospitalization
22. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
23. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer:Implications for combination therapies and early response prediction
24. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
25. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
26. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
27. Patients’ evaluation of aftercare following hospitalization for COVID-19:satisfaction and unmet needs
28. Acute COVID-19 treatment is not associated with health problems 2 years after hospitalization
29. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
30. Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease
31. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC
32. B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients
33. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application
34. Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
35. Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
36. Diagnostic accuracy of eNose “breathprints” for therapeutic drug monitoring of Tacrolimus trough levels in lung transplantation
37. Treatment Satisfaction of Patients With Advanced Non–Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL)
38. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
39. Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.
40. Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC
41. Supplementary Data from Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
42. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours
43. Diagnostic performance of electronic nose technology in chronic lung allograft dysfunction
44. Immunological profiling in long COVID:overall low grade inflammation and T-lymphocyte senescence and increased monocyte activation correlating with increasing fatigue severity
45. Diagnostic accuracy of eNose 'breathprints' for therapeutic drug monitoring of Tacrolimus trough levels in lung transplantation
46. Trends in the epidemiology of small-cell lung cancer:a Dutch nationwide population-based study over 1989–2020
47. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma:a phase II clinical trial
48. Safety of extended interval dosing immune checkpoint inhibitors:a multicenter cohort study
49. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's:Exploration of efficacy of unselected treatment in a multicenter cohort study
50. Impact of centralization of care for malignant peritoneal mesothelioma:A historical cohort study from the Dutch mesothelioma expert centers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.